ea0089t5 | Trials In Progress | NANETS2022
Jimenez Camilo
, Hadoux Julien
, Del Rivero Jaydira
, Das Satya
, Iliopoulos Othon
, Sultanbaev Alexander
, Artamonova Elena
, Jonasch Eric
, Pacak Karel
, Wang Wei
, Jin Fan
, S. Naik Girish
, Capdevila Jaume
Background: Patients with advanced pheochromocytoma/paraganglioma (PPGL) or pancreatic neuroendocrine tumor (panNET) are in need of novel targeted therapies. Hypoxia-inducible factor 2α (HIF-2α) is one of the key oncogenic drivers in neuroendocrine tumors. Hypoxia signaling pathway alterations or other mechanisms that stabilize HIFs are common in some PPGLs and panNETs. Belzutifan (MK-6482), a HIF-2α inhibitor, has shown antitumor activity in advanced renal cell...